Tomasz M. Beer

37.6k total citations · 7 hit papers
406 papers, 18.0k citations indexed

About

Tomasz M. Beer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Tomasz M. Beer has authored 406 papers receiving a total of 18.0k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Pulmonary and Respiratory Medicine, 169 papers in Oncology and 105 papers in Cancer Research. Recurrent topics in Tomasz M. Beer's work include Prostate Cancer Treatment and Research (250 papers), Radiopharmaceutical Chemistry and Applications (71 papers) and Prostate Cancer Diagnosis and Treatment (63 papers). Tomasz M. Beer is often cited by papers focused on Prostate Cancer Treatment and Research (250 papers), Radiopharmaceutical Chemistry and Applications (71 papers) and Prostate Cancer Diagnosis and Treatment (63 papers). Tomasz M. Beer collaborates with scholars based in United States, Canada and France. Tomasz M. Beer's co-authors include Celestia S. Higano, Mark Garzotto, Howard I. Scher, W. David Henner, Michael J. Morris, Joshi J. Alumkal, Christopher W. Ryan, Motomi Mori, Kristine M. Eilers and Kim N. and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Tomasz M. Beer

392 papers receiving 17.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

2008 1.7k citations Howard I. Scher, Michael J. Morris et al. profile →
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

2009 1.7k citations Chris Tran, Samedy Ouk et al. Science profile →
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. profile →
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

2010 809 citations Howard I. Scher, Tomasz M. Beer et al. profile →
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

2012 621 citations Celestia S. Higano, Tomasz M. Beer et al. profile →
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

2013 436 citations Celestia S. Higano, Joshi J. Alumkal et al. profile →
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

2023 168 citations Tomasz M. Beer, Eric A. Klein et al. profile →

Peers

Countries citing papers authored by Tomasz M. Beer

Since Specialization

Citations

This map shows the geographic impact of Tomasz M. Beer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomasz M. Beer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomasz M. Beer more than expected).

Fields of papers citing papers by Tomasz M. Beer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomasz M. Beer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomasz M. Beer. The network helps show where Tomasz M. Beer may publish in the future.

Co-authorship network of co-authors of Tomasz M. Beer

This figure shows the co-authorship network connecting the top 25 collaborators of Tomasz M. Beer. A scholar is included among the top collaborators of Tomasz M. Beer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomasz M. Beer. Tomasz M. Beer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance 2024 ·Veterinary and Comparative Oncology ·(unknown), Bernard Séguin, Christiane V. Löhr, Tomasz M. Beer, (unknown), Stephen A. Ramsey, George Thomas	1
2	Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting 2024 ·Blood ·Tomasz M. Beer, (unknown), Dee Lin, (unknown), (unknown), Laura Hester, Bingcao Wu, (unknown)	1
3	Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial 2024 ·European Urology ·Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, (unknown), (unknown), Michael J. Morris	7
4	Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Eric A. Klein, Sarina Madhavan, Tomasz M. Beer, Chetan Bettegowda, Minetta C. Liu, Anne‐Renee Hartman, Allan Hackshaw	15
5	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER 2022 ·European Journal of Cancer ·Anthony M. Joshua, Andrew J. Armstrong, Megan Crumbaker, Howard I. Scher, Johann S. de Bono, Bertrand Tombal, Maha Hussain, Cora N. Sternberg, Silke Gillessen, Joan Carles, Karim Fizazi, Ping Lin, William Duggan, Jennifer Sugg, David Russell, Tomasz M. Beer	21
6	Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial 2020 ·Journal of Medical Internet Research ·June M. Chan, Erin L. Van Blarigan, Crystal S. Langlais, Shoujun Zhao, Justin Ramsdill, (unknown), (unknown), Elizabeth Wang, (unknown), Elizabeth R. Kessler, Tomasz M. Beer, Karen S. Lyons, Jeanette M. Broering, Peter R. Carroll, Stacey A. Kenfield, Kerri M. Winters‐Stone	31
7	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity 2019 ·Molecular Cancer Research ·Rahul Aggarwal, David A. Quigley, Jiaoti Huang, Li Zhang, Tomasz M. Beer, Matthew B. Rettig, (unknown), Martin Gleave, George Thomas, Adam Foye, Denise Playdle, Paul Lloyd, Kim N., Christopher P. Evans, Primo N. Lara, Felix Y. Feng, Joshi J. Alumkal, Eric J. Small	40
8	DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer 2018 ·Journal of the National Comprehensive Cancer Network ·Eric Lu, George Thomas, Yiyi Chen, Alexander W. Wyatt, Paul Lloyd, Jack Youngren, David A. Quigley, Raymond C. Bergan, (unknown), Tomasz M. Beer, Felix Y. Feng, Eric J. Small, Joshi J. Alumkal	8
9	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial 2018 ·JMIR Research Protocols ·Kerri M. Winters‐Stone, Stacey A. Kenfield, Erin L. Van Blarigan, Esther Moe, Justin Ramsdill, (unknown), (unknown), (unknown), Elizabeth R. Kessler, Ömer Küçük, Theresa Gillespie, Karen S. Lyons, Tomasz M. Beer, Jeanette M. Broering, Peter R. Carroll, June M. Chan	9
10	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer 2018 ·Clinical Cancer Research ·Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary‐Ellen Taplin, James S. Babb, Ethan Barnett, (unknown), Xiaomei Liu, Dirk F. Moore, (unknown), Tomasz M. Beer	52
11	CT–Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield 2017 ·Journal of Vascular and Interventional Radiology ·(unknown), (unknown), Gabby B. Joseph, Adam Foye, (unknown), Daria Motamedi, Jack Youngren, George Thomas, Jiaoti Huang, Rahul Aggarwal, Joshi J. Alumkal, Tomasz M. Beer, Eric J. Small, Thomas M. Link	24
12	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL 2017 ·Prostate Cancer and Prostatic Diseases ·Alan H. Bryce, Joshi J. Alumkal, Andrew J. Armstrong, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Dana E. Rathkopf, Yohann Loriot, Johann S. de Bono, Bertrand Tombal, Sarang Abhyankar, Po‐Han Lin, Andrew Krivoshik, D. Phung, Tomasz M. Beer	71
13	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer 2014 ·Cancer Immunology Research ·Julie N. Graff, Sachin Puri, Carlo Bifulco, Bernard A. Fox, Tomasz M. Beer	29
14	Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer 2013 ·Clinical Cancer Research ·Christine M. Barnett, Michael C. Heinrich, Jeong Ho Lim, Dylan Nelson, Carol Beadling, Andrea Warrick, Tanaya Neff, Celestia S. Higano, Mark Garzotto, David Z. Qian, Christopher L. Corless, George Thomas, Tomasz M. Beer	19
15	Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer 2010 ·Cancer Research ·(unknown), Craig Horbinski, Mark Garzotto, David Z. Qian, Tomasz M. Beer, Natasha Kyprianou	288
16	ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21 2010 ·Cancer Research ·Hao Geng, Brooks L. Rademacher, Janét Pittsenbarger, (unknown), (unknown), (unknown), Anne Myrthue, Mark Garzotto, Peter S. Nelson, Tomasz M. Beer, David Z. Qian	30
17	Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies 2009 ·Clinical Cancer Research ·David Z. Qian, (unknown), Catherine O′Brien, Ilsa M. Coleman, Mark Garzotto, Lawrence D. True, Celestia S. Higano, (unknown), Paul H. Lange, Peter S. Nelson, Tomasz M. Beer	14
18	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer breakdown → 2009 ·Science ·Chris Tran, Samedy Ouk, Nicola J. Clegg, Yu Chen, Philip A. Watson, Vivek Arora, John Wongvipat, Peter Smith‐Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, Derek S. Welsbie, (unknown), Celestia S. Higano, Tomasz M. Beer, David T. Hung, Howard I. Scher, Michael E. Jung, Charles L. Sawyers	1689
19	Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 2007 ·Clinical Cancer Research ·(unknown), Tomasz M. Beer, Celestia S. Higano, Lawrence D. True, Robert L. Vessella, Paul H. Lange, Mark Garzotto, Peter S. Nelson	55
20	Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer 2004 ·Cancer Research ·Tomasz M. Beer, Milind Javle, W. David Henner, Donald L. Trump	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact